These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 32593299)
1. Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets. Wang H; Wang X; Xu L; Zhang J; Cao H BMC Pediatr; 2020 Jun; 20(1):314. PubMed ID: 32593299 [TBL] [Abstract][Full Text] [Related]
2. Age related gene DST represents an independent prognostic factor for MYCN non-amplified neuroblastoma. Wang H; Wang X; Xu L; Zhang J; Cao H BMC Pediatr; 2021 Jun; 21(1):272. PubMed ID: 34116676 [TBL] [Abstract][Full Text] [Related]
3. Prognostic analysis of E2F transcription factors E2F1 and E2F3 in four independent pediatric neuroblastoma cohorts. Wang H; Wang X; Xu L; Zhang J BMC Pediatr; 2022 Jun; 22(1):376. PubMed ID: 35764946 [TBL] [Abstract][Full Text] [Related]
5. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines. Aygun N; Altungoz O Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774 [TBL] [Abstract][Full Text] [Related]
6. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients. Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155 [TBL] [Abstract][Full Text] [Related]
7. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma. Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373 [TBL] [Abstract][Full Text] [Related]
8. Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma. Eberhardt A; Hansen JN; Koster J; Lotta LT; Wang S; Livingstone E; Qian K; Valentijn LJ; Zheng YG; Schor NF; Li X Oncotarget; 2016 Sep; 7(39):63629-63639. PubMed ID: 27571165 [TBL] [Abstract][Full Text] [Related]
9. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma. Hallett RM; Seong AB; Kaplan DR; Irwin MS Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694 [TBL] [Abstract][Full Text] [Related]
10. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma. Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156 [TBL] [Abstract][Full Text] [Related]
12. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma. Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848 [TBL] [Abstract][Full Text] [Related]
13. Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in Zhao M; Gu W; Liu F; Yu L; Shu Y; Liu L; Hu J; Liu Y; Tang H; Mao J Pediatr Dev Pathol; 2023; 26(2):124-132. PubMed ID: 36775958 [TBL] [Abstract][Full Text] [Related]
14. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595 [TBL] [Abstract][Full Text] [Related]
15. A signature based on five immune-related genes to predict the survival and immune characteristics of neuroblastoma. Ma K; Zhang P; Xia Y; Dong L; Li Y; Liu L; Liu Y; Wang Y BMC Med Genomics; 2022 Nov; 15(1):242. PubMed ID: 36419120 [TBL] [Abstract][Full Text] [Related]
16. Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis. Wang H; Wang X; Xu L Ital J Pediatr; 2023 Oct; 49(1):145. PubMed ID: 37904225 [TBL] [Abstract][Full Text] [Related]
17. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma. Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965 [TBL] [Abstract][Full Text] [Related]
18. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915 [TBL] [Abstract][Full Text] [Related]
19. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification. Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009 [TBL] [Abstract][Full Text] [Related]
20. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma. He X; Qin C; Zhao Y; Zou L; Zhao H; Cheng C Cancer Commun (Lond); 2020 Mar; 40(2-3):105-118. PubMed ID: 32237073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]